Glenmark settles patent case with Janssen for tablets

Glenmark Pharmaceuticals today said it has settled litigation with Janssen Pharmaceuticals Inc over patent actions regarding generic oral contraceptive Norgestimate and Ethinyl Estradiol tablets.

Glenmark Generics Inc, subsidiary of Glenmark Generics Ltd, has announced the settlement of litigation pending between Glenmark and Janssen Pharmaceuticals Inc (Janssen) over patent actions concerning Norgestimate and Ethinyl Estradiol tablets, Glenmark Pharmaceuticals said in a statement.

Under the terms of the settlement agreements, Glenmark will be able to market and distribute its generic tablets under a royalty bearing licence from Janssen on December 31, 2015, or earlier under certain circumstances, it added.

As per the IMS Health data, the total US sales for the tablets were nearly USD 397 million for the twelve month period ended June 2012, Glenmark said.

The company's tablets in the strengths of 0.18/0.025 mg,0.215/ 0.025 mg and 0.25/0.025 mg are generic version of Janssen's Ortho Tricyclen LO tablets, it added.

Shares of Glenmark Pharmaceuticals today closed at Rs 431 per scrip on BSE, down 1.45 per cent from its previous close.